deposition in the brain correlated with the level of cognitive impairment. 11, 16, 18, 20 Also, several autopsy studies have shown amyloid plaques are present in the brain as early as 2 hours after injury and persist even 2.5 years later. 11, 23, 30 Furthermore, the likelihood of amyloid plaque deposition was more evident in patients with APOE ε4 expression (50% in Apo-E4-expressing patients vs 30% in the nonApo-E4-expressing group). The Apo-E4-expressing individuals also performed worse on cognitive tests at time points more distant from the injury. 4, 19 Given the increased risk for AD noted in Apo-E4-expressing patients, the increased likelihood for amyloid plaque deposition in TBI patients with the APOE ε4 allele supports the reported link between severe TBI and AD-like dementia. 19 In this study, we hypothesized that people who express Apo-E4 will accumulate more amyloid in the brain after TBI.
Recently, a single PET scan ([11C] PiB) of the head conducted within 1 year of TBI showed that amyloid deposition correlates with histological findings of amyloid plaques in the brain of people who died shortly after the lone scan. 10 In this study we used 18 F-AV-45 (florbetapir F18), which has a longer half-life and has a high binding affinity for fibrillar amyloid, 3, 6 as a more practical tool for imaging the head of TBI survivors. In previous AD studies, florbetapir F18 binding was characterized and found to correlate with cognitive and mood disorders. 3, 6, 12, 17, 35 In this prospective study, the aim was to conduct serial imaging in TBI survivors to determine the deposition profile within a number of brain regions at subacute (~ 30 days after injury) and chronic (12 and 24 months) time points after injury.
case reports case 1

History
This 50-year-old man had experienced a severe TBI (Glasgow Coma Scale [GCS] score of 3) due to a motor vehicle collision (Table 1) . CT scans showed that he had a 3-mm midline shift. Additionally, a subdural hematoma was reported in the left frontal and temporoparietal cortex. To lower intracranial pressure, a left hemicraniectomy was performed (Fig. 1A and B) .
Serial Florbetapir F18 PET Imaging
Following discharge from Parkland Hospital (Dallas, Texas) the patient underwent scanning with the Siemens ECAT HR PET scanner on Day 30 after the injury, and subsequent scanning was performed at 1 and 2 years after injury. To label the fibrillar amyloid, 370 MBq (10 mCi) of the florbetapir F18 tracer (AVID Radiopharmaceuticals) was injected. Following a 50-minute washout period, a 10-minute continuous brain PET scan was conducted. Images were reconstructed immediately after the 10-minute scan. We acquired individual measures of amyloid deposition for specific brain structures. A hierarchical regression technique was used to analyze the data. Images were spatially normalized to the Montreal Neurological Institute (MNI) space using SPM8 and special image templates developed for florbetapir F18 from the brains of normal controls. These values were used to extract a value of amyloid from the data. A negative scan was defined as one in which the majority of the tracer was bound in the white matter ( Fig. 2A and B) . Initially, the scans were analyzed for significant accumulation of tracer in the gray matter. A scan is considered positive if tracer retention is evident primarily in the cortical gray areas (Fig. 2C) . After spatial normalization, volumes of interest (VOIs) that were derived from MRI data from the MNI atlas were applied using internally developed MATLAB code to extract count density from 12 brain regions (anterior and posterior cingulate gyrus, dorsolateral prefrontal cortex, frontal cortex, left and right hippocampus, left and right anterior putamen, left and right caudate nucleus, left and right thalamus, occipital cortex, orbital frontal cortex, parietal cortex, precuneus, temporal cortex). Standard uptake value ratios (SUVRs) were computed for VOIs and a cerebellar VOI was extracted to determine nonspecific binding. As determined previously in healthy controls who underwent serial scanning performed by our research group and others, 24 a change in SUVRs greater than 8% per year was deemed to be a meaningful increase. All aspects of the study described herein were approved by the institutional review board at the University of Texas Southwestern Medical Center (Dallas, Texas) prior to the initiation of any study-specific procedures.
APOE Genotyping
To test for apolipoprotein E (APOE) status, venous blood samples (8 ml) were collected into EDTA tubes, aliquoted into 1-ml tubes, and immediately frozen at −80°C. Genomic DNA was isolated by standard protocols. Genotypes were determined by Taqman assays (Applied Biosystems, Inc.).
Results
Prior to the scanning procedures, the Mini-Mental State Examination (MMSE), the Disability Rating Scale (DRS), and the Rivermead Post-Concussion Symptom Questionnaire 13 were administered. The patient had a moderate-to-severe cognitive impairment, as indicated by an MMSE score of 19 at the 1-month time point. He also had a moderately severe disability (DRS score of 9). Scores of 29 and 4 for the MMSE and DRS (moderate), respectively, indicated improved cognition and function at the 12-month time point. Also, the patient had a lower good recovery as indicated by a Glasgow Outcome ScaleExtended (GOS-E) score of 7 at Year 1. In contrast, at the 24-month time point, a worsening of both cognition (MMSE score of 22) and function (DRS score of 7) was observed ( Table 2) . At 1 month after injury, the patient displayed severe symptoms, which improved slightly at the 12-(moderate) and 24-(moderate) month time points (Table 3). He suffered from headaches, nausea, balance, dizziness, fatigue, and memory problems ( Table 3 ). The results of APOE genotyping showed that the patient's status was APOE e3/e3. Comparison of the patient's florbetapir F18 PET scans from all imaging time points to scans obtained in a healthy age-matched control did not show any gross accumulation of amyloid within the cortical gray matter (Fig. 2) , and thus analysis of amyloid levels within specific brain regions was performed. SUVR values from the 12 brain regions are listed in Table 4 . In the patient in Case 1, comparison of region-specific SUVRs at 1 month with the 12-month scan only showed a decrease in amyloid in the hippocampus and caudate nucleus regions. Within the hippocampus, 16% and 12% decreases in amyloid were observed in the left and right hippocampus, respectively, at Year 1. A similar finding was observed in the left (−18%) and right (−18%) caudate nucleus. A decrease in SUVR at the 12-month time point signifies amyloid clearance from the brain since the initial scan. In the caudate nucleus and left hippocampal brain regions, no change in amyloid deposition was observed at the 24-month time point. In contrast, a 15% increase of amyloid was found in the right hippocampus at the 24-month time point compared with the SUVR values collected at 12 months (Table  4 , Fig. 3 ). With respect to post-TBI symptoms, worsening in memory problems (Rivermead symptom questionnaire) and cognitive outcomes (MMSE) was also observed at the 24-month time point compared with results obtained at 12 months (Tables 2 and 3) .
case 2
History
This 37-year-old man was involved in a motor vehicle collision and was admitted to Parkland Hospital with a severe TBI (GCS score of 4). A 1-to 2-mm midline shift and subarachnoid hemorrhage in the right frontotemporoparietal cortex were identified by CT. A hemicraniectomy was performed to reduce intracranial pressure in the right hemisphere. This patient also suffered a right hemispheric ischemic stroke during his hospital stay ( Fig. 1C and D) . He subsequently underwent 1.5 years of rehabilitation to improve swallowing, walking, and other motor abilities.
Serial Florbetapir F18 PET Imaging
Scanning was performed at 1, 12, and 24 months after TBI using the Siemens ECAT HR PET scanner. At each time point, the patient was injected with the florbetapir F18 tracer and a brain scan was conducted. Images were processed as described in Case 1, and 12 brain regions were surveyed to collect SUVRs to ascertain if changes in amyloid deposition occurred in a particular brain region.
APOE Genotyping
As in Case 1, venous blood samples (8 ml) were collected into EDTA tubes, aliquoted into 1 ml tubes, and immediately frozen at −80°C. Genomic DNA was isolated by standard protocols. Genotypes were determined by Taqman assays.
Results
At the initial scan (~ 1 month after injury), the patient had a DRS rating of 15 (severe disability), an MMSE score of 23 (moderate cognitive deficit), and Rivermead symptom scores indicating severe symptoms. At the later time points, the DRS score improved to 9 and 5 at the 12-and 24-month time points, respectively. The MMSE score improved to 29 at both 12 and 24 months. At Year 1, the patient had an upper moderate disability and Rivermead symptom scoring indicated severe symptoms. Improvement of symptom scoring to moderate and GOS-E scoring to low-good recovery was observed at 24 months. The symptoms reported for this patient were headaches, nausea, vomiting, balance, dizziness, fatigue, irritability, sadness, and memory problems (Table 5) . Compared with the agematched control, no evidence of a global increase of florbetapir F18 was found within the cortical tissue at the 1-, 12-, or 24-month time points (Fig. 2G-I ). Due to the infarct area in the right hemisphere and possible data reliability issues, we only focused on the SUVR values from brain regions outside of the affected area. In the left hemisphere, compared with the 1-month scan, we observed an increase in amyloid at 12 months in the left anterior putamen (+11%) and a decrease in the left caudate nucleus (−48%), occipital cortex (−21%), and precuneus (−19%) brain regions. No increase in brain amyloid was observed at 24 months in any of the regions that were surveyed. Within the left anterior putamen (−12%), occipital cortex (−15%), and precuneus (−11%), compared with 12 months, a decrease in amyloid was measured at 24 months after TBI (Table 6 , Fig. 4 ). The APOE genotype for this patient was APOE ε2/ε3.
discussion
In this study, we demonstrate the feasibility of obtaining serial scans in people who have survived a severe TBI event. Also, we show that in our sample of 2 TBI patients, brain scans obtained in the patient with the poorer outcome showed more amyloid accumulation than scans obtained in the patient with the better outcome or in healthy controls. The novelty of this study is in its conduct of se- rial scanning to compare the subacute (~ 30 days after TBI) amyloid levels to levels demonstrated by subsequent scans performed at 12 and 24 months after injury to determine the rate of change of amyloid in the brain within each person. By conducting serial scans, we can elucidate whether increases in amyloid deposition predict worsening of amyloid accumulation and/or neurodegeneration. Also, this methodology sheds light on the dynamics of amyloid deposition rates and patterns during the acute and chronic phases of TBI. Use of florbetapir F18, which has a substantial half-life (90 minutes), was instrumental in identifying both clearance and accumulation of amyloid at 12 and 24 months after injury when compared with SUVRs collected during the initial scan (~ 1 month after injury) within each subject. When surveying specific brain regions, we found that both of the patients experienced increases in brain amyloid after TBI (Figs. 3 and 4) . Originally, we hypothesized that accumulation of amyloid in TBI survivors only occurs in individuals with poor outcomes. In contrast, as defined by the participants' DRS and GOS-E scores, we found that TBI patients with both moderate-to-severe and moderate-to-good outcomes exhibited increases in amyloid deposition in the brain. A main difference that we observed is that the patient with a moderate-to-good outcome (Case 1) exhibited a lower SUVR percent change (mean 15%) than the patient in Case 2, who experienced a moderate-to-poor outcome and a mean change of amyloid of about 26% at the 12-month time point. These differences may be related to the initial severity of their injuries.
To determine region-specific changes, we decided to compare the SUVRs between the 3 time points to determine if fluctuations exist throughout cortical and subcortical structures. This approach proved to be valuable in comparing the changes in brain amyloid within these serial scans. As shown in Tables 4 and 6 , only a small number of brain regions were affected within each individual. Use of florbetapir F18 as a clinical marker for brain regions with heightened amyloid load may prove useful in predicting the onset of long-term cognitive and mood disorders. For example, the patient in Case 1 had an initial increase in amyloid in the left and right hippocampi that was reduced by 12 months after TBI. In contrast to the 12-month scan, the 24-month scan showed a greater elevation of amyloid in the right hippocampus. This change may be directly related to the onset of severe memory problems, which was reported at the 24-month appointment by the patient in Case 1 and his family. Comparison of the SUVR values from multiple time points within a single patient may yield more reliable data on the timing of amyloid deposition after TBI. If the individuals who may be prone to accumulate amyloid can be identified, anti-amyloid therapies that become available in the future may provide an ideal treatment to reduce amyloid-related chronic secondary brain injury.
In previous studies, the likelihood of amyloid plaque deposition was more evident in TBI patients with Apo-E4 expression (50% in Apo-E4-expressing patients vs 30% in the non-Apo-E4-expressing group). The Apo-E4-expressing individuals also performed worse on cognitive tests at longer periods of time after injury. 2, 4, 5, 9, 14, 19, 21, 22, 28, 33, 34 Given the increased risk for AD noted in Apo-E4-expressing patients, the increased likelihood for amyloid plaque deposition in APOE ε4 carriers with TBI supports the reported link between severe TBI and AD. 4, 7, 9, 14, 19, 22, 25, 27, 28, [31] [32] [33] [34] Initially, we hypothesized that only Apo-E4 expressers would accumulate amyloid in the brain after TBI. Unfortunately, due to our limited sample size, we were unable to test our hypothesis. In our 2 cases, the patients' APOE genotypes were as follows: APOE ε3/ε3 in Case 1 and APOE ε2/ε3 in Case 2 (Table 1) .
There are several recognized limitations of this study. Primarily, the limited sample size, lack of controls (trauma without TBI), variability of the injuries, and diverse pattern of amyloid accumulation between the participants limit the conclusions that can be drawn. However, the primary purpose of this study was to assess a serial imaging methodology. Using purposive sampling, we enrolled TBI patients who had improvements in neurological outcomes and were most likely to survive and participate in followup procedures, since the severe TBI population suffers from high morbidity and low follow-up. As a future direction, we plan to enroll TBI patients with both poor and good outcomes to determine if amyloid deposition rates differ between individuals with good outcomes and those with poor outcomes. With respect to the diversity of amyloid deposition in the brain, the difference observed here may be due to the mode and location of the injury, which is highly variable within the TBI population. We also recognize that administration of an extensive neuropsychological battery would prove useful to determine relationships between amyloid deposition and cognitive/mood deficits. In addition to neuropsychological testing, in future definitive studies, we will also conduct diffusion tensor imaging and functional connectivity MRI to measure the integrity of the white matter within these populations.
In conclusion, this research sheds light on the use of florbetapir F18 PET imaging as a method to detect/monitor amyloid accumulation in the brain of TBI survivors. We found that within a 2-year period after severe TBI, amyloid accumulates at both early and late postinjury time points. By conducting follow-up scans, we were able to identify specific brain regions where amyloid accumulated after TBI as potential biomarkers for cognitive and/ or mood deficits. As a future direction, administration of a thorough neuropsychological battery and MRI may prove useful in determining how amyloid deposition in certain brain structures correlates with cognitive performance and structural abnormalities after TBI at both the early and late time points within each individual.
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